Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic dendritic cells + autologous renal cell carcinoma tumor-derived cells
- Development stage
- Unknown
- Lead developer
- Mendus
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intranodal, Intravenous
01
Overview
This therapy is a personalized cancer vaccine composed of allogeneic dendritic cells (DCs) fused or combined with autologous (patient-derived) renal cell carcinoma (RCC) tumor-derived cells. The approach leverages the potent antigen-presenting capacity of healthy donor DCs to present patient-specific tumor antigens from their own RCC tissue. The resulting hybrid or fusion vaccine is designed to stimulate the patient's immune system to recognize and attack RCC tumors by presenting a broad array of relevant antigens in an immunogenic context. Clinical studies have evaluated this strategy in patients with metastatic RCC, showing feasibility and safety, with some evidence for immune activation and clinical responses such as partial response or disease stabilization[1][2][3]. This modality is under investigation primarily for advanced/metastatic renal cell carcinoma.
- Other names
- alloDC-autologous RCC fusion vaccine
02
Targets
Patient-specific renal cell carcinoma tumor-associated antigens presented as peptide-MHC complexes to T-cell receptors
Beyond the preview
Go deeper on allogeneic dendritic cells + autologous renal cell carcinoma tumor-derived cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic dendritic cells + autologous renal cell carcinoma tumor-derived cells.